Dysregulation of non-coding RNAs in gastric cancer

Gastric cancer(GC) is one of the most common cancers in the world and a significant threat to the health of patients, especially those from China and Japan. The prognosis for patients with late stage GC receiving the standard of care treatment, including surgery, chemotherapy and radiotherapy, remai...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 21; no. 39; pp. 10956 - 10981
Main Author Yang, Qing
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 21.10.2015
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Gastric cancer(GC) is one of the most common cancers in the world and a significant threat to the health of patients, especially those from China and Japan. The prognosis for patients with late stage GC receiving the standard of care treatment, including surgery, chemotherapy and radiotherapy, remains poor. Developing novel treatment strategies, identifying new molecules for targeted therapy, and devising screening techniques to detect this cancer in its early stages are needed for GC patients. The discovery of non-coding RNAs(nc RNAs), primarily micro RNAs(mi RNAs) and long non-coding RNAs(lnc RNAs), helped to elucidate the mechanisms of tumorigenesis, diagnosis and treatment of GC. Recently, significant research has been conducted on non-coding RNAs and how the regulatory dysfunction of these RNAs impacts the tumorigenesis of GC. In this study, we review papers published in the last five years concerning the dysregulation of noncoding RNAs, especially mi RNAs and lnc RNAs, in GC. We summarize instances of aberrant expression of the ncR NAs in GC and their effect on survival-related events, including cell cycle regulation, AKT signaling, apoptosis and drug resistance. Additionally, we evaluate how nc RNA dysregulation affects the metastatic process, including the epithelial-mesenchymal transition, stem cells, transcription factor activity, and oncogene and tumor suppressor expression. Lastly, we determine how ncR NAs affect angiogenesis in the microenvironment of GC. We further discuss the use of ncR NAs as potential biomarkers for use in clinical screening, early diagnosis and prognosis of GC. At present, no ideal ncR NAs have been identified as targets for the treatment of GC.
Bibliography:Gastric cancer;Dysregulation;Non-coding RNA;Tumori
Qing Yang;Ren-Wen Zhang;Peng-Cheng Sui;Hai-Tao He;Lei Ding;Department of Pathogenobiology, College of Basic Medical Sciences, Jilin University
Gastric cancer(GC) is one of the most common cancers in the world and a significant threat to the health of patients, especially those from China and Japan. The prognosis for patients with late stage GC receiving the standard of care treatment, including surgery, chemotherapy and radiotherapy, remains poor. Developing novel treatment strategies, identifying new molecules for targeted therapy, and devising screening techniques to detect this cancer in its early stages are needed for GC patients. The discovery of non-coding RNAs(nc RNAs), primarily micro RNAs(mi RNAs) and long non-coding RNAs(lnc RNAs), helped to elucidate the mechanisms of tumorigenesis, diagnosis and treatment of GC. Recently, significant research has been conducted on non-coding RNAs and how the regulatory dysfunction of these RNAs impacts the tumorigenesis of GC. In this study, we review papers published in the last five years concerning the dysregulation of noncoding RNAs, especially mi RNAs and lnc RNAs, in GC. We summarize instances of aberrant expression of the ncR NAs in GC and their effect on survival-related events, including cell cycle regulation, AKT signaling, apoptosis and drug resistance. Additionally, we evaluate how nc RNA dysregulation affects the metastatic process, including the epithelial-mesenchymal transition, stem cells, transcription factor activity, and oncogene and tumor suppressor expression. Lastly, we determine how ncR NAs affect angiogenesis in the microenvironment of GC. We further discuss the use of ncR NAs as potential biomarkers for use in clinical screening, early diagnosis and prognosis of GC. At present, no ideal ncR NAs have been identified as targets for the treatment of GC.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Correspondence to: Qing Yang, PhD, Professor, Department of Pathogenobiology, College of Basic Medical Sciences, Jilin University, 126 Xinmin Street, Changchun 130012, Jilin Province, China. yangq@jlu.edu.cn
Telephone: +86-431-85619439 Fax: +86-431-85619105
Author contributions: Yang Q designed and critically revised the paper; Zhang RW, Sui PC, He HT and Ding L wrote the paper.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v21.i39.10956